MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways

Abstract

Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in the majority of breast cancer patients, due to poorly understood… (More)
DOI: 10.1038/onc.2010.487

Topics

9 Figures and Tables

Cite this paper

@article{Rao2011MicroRNA221222CB, title={MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways}, author={X Rao and Gianpiero Di Leva and M Li and Fu Fang and Caitlin Devlin and Cori Hartman-Frey and Matthew E. Burow and Mircea Ivan and C. M. Croce and Kenneth P. Nephew}, journal={Oncogene}, year={2011}, volume={30}, pages={1082-1097} }